News · Heart & Metabolic
A daily weight-loss pill hit 10% in a mid-stage trial
A Lancet phase 2 trial of 310 adults found the oral GLP-1 drug elecoglipron produced up to 10.5% weight loss in 26 weeks against 0.6% on placebo, with no injections and no food restrictions.
Based on a peer-reviewed phase 2 trial in The Lancet
- The VISTA phase 2 trial randomized 310 adults across seven countries to elecoglipron or placebo for 36 weeks, published in The Lancet.
- Participants had obesity, or overweight with at least one weight-related condition, and did not have type 2 diabetes. Mean starting weight was 106.9 kg.
- At week 26, weight change ranged from -2.6% on the lowest dose to -10.5% on the highest, against -0.6% for placebo.
- Between 40.4% and 88.8% of those on the drug lost at least 5% of body weight, versus 15.6% on placebo.
- Unlike some oral GLP-1 drugs, it is taken once daily without food or fluid restriction.
- Side effects were common: 84% to 98% of participants on the drug reported an adverse event, against 84% on placebo. Nausea, constipation, diarrhea, headache and vomiting led the list.
- Only 75% completed the assigned treatment. This is a phase 2 dose-ranging study funded by AstraZeneca, with no head-to-head comparison against injectable drugs.
The needle has always been the sticking point. Whatever the results, a weekly injection asks something of people that a tablet does not. A trial in The Lancet reports a pill that got close to injectable territory.
Elecoglipron is an oral small-molecule glucagon-like peptide-1 receptor agonist administered once daily without food or fluid restriction. In a phase 2 trial across seven countries, the highest dose produced about ten times the weight loss of placebo over 26 weeks.
Why “small molecule” is the point
The GLP-1 drugs people know are peptides, chains of amino acids that the digestive system dismantles. That is why they are injected, and why the one existing oral version demands an empty stomach, a precise amount of water and a wait before eating.
A small molecule is sturdier. It survives the gut, which is what allows the once-daily dosing without food or fluid restriction that separates this drug from what came before. Until now, that combination had not been demonstrated at this level of weight loss.
The trial
The trial was a double-blind, randomized, controlled, phase 2 dose-ranging study with a total treatment duration of 36 weeks, recruiting from research centers and hospitals in Australia, Canada, Germany, Japan, Taiwan, the UK, and the USA.
Participants were adults living with obesity or with overweight with at least one weight-related condition and without type 2 diabetes. Of 472 screened, 310 participants were randomly assigned across five dosing regimens and placebo. Mean age was 48.4 years, 73% were female, and mean bodyweight was 106.9 kg.
What it did
At week 26, the estimated mean change from baseline in bodyweight was between -2.6% on the lowest dose and -10.5% on the highest, compared with -0.6% with placebo.
The proportion reaching a meaningful threshold moved just as sharply. The estimated proportion of participants reaching weight reductions of at least 5% at week 26 was 40.4% to 88.8% with elecoglipron versus 15.6% with placebo.
For a tablet with no dietary choreography attached, 10.5% is a serious number.
The parts that temper it
Side effects were near-universal, though so were they on placebo. Adverse events were reported by 84% to 98% of participants across elecoglipron doses compared with 84% in the placebo group, the most common being nausea, constipation, diarrhea, headache, and vomiting.
More telling is who stayed. 288 participants completed the study, but only 231, or 75%, completed the assigned treatment. A quarter of people stopped taking the drug they were assigned, which is the kind of detail a headline percentage hides.
This is also phase 2: a dose-finding exercise in 310 people, not a test of whether anyone lives longer or healthier. No injectable comparator was included, so any claim that the pill matches semaglutide or tirzepatide is a cross-trial guess rather than a finding. And the study was funded by AstraZeneca, which is developing it.
What it signals
The authors set the appropriate ceiling on their own result, describing clinically meaningful weight reductions and a safety and tolerability profile consistent with the GLP-1 receptor agonist class, supporting phase 3 investigation.
That is the honest summary. Not a replacement for injections, not yet available, and not proven on the outcomes that matter most. But the barrier that kept these drugs in a syringe looks increasingly like an engineering problem rather than a biological one.
People also ask
Is this as good as the injections?
The trial cannot say, because it did not compare them. Elecoglipron reached up to 10.5% weight loss at 26 weeks, which sits in a similar range to semaglutide's published results at comparable timepoints but below tirzepatide's. Comparing across separate trials with different populations and durations is unreliable. Only a head-to-head trial would settle it, and none has been run.
What makes an oral GLP-1 different?
Most GLP-1 drugs are peptides, which the gut destroys, so they are injected. Elecoglipron is a small molecule, meaning a more chemically robust compound that survives digestion. Practically, the trial's notable detail is that it is taken once daily without food or fluid restriction, unlike oral semaglutide, which requires fasting and careful timing with water.
How bad were the side effects?
Common, and typical of the drug class. Adverse events were reported by 84% to 98% of participants across elecoglipron doses, compared with 84% in the placebo group, most often nausea, constipation, diarrhea, headache and vomiting. The placebo figure being 84% is a reminder that 'adverse event' captures everything reported, not just drug effects. That said, only 75% of participants completed the assigned treatment, which suggests tolerability was a real issue for some.
When could this be available?
Not soon. This is a phase 2 dose-ranging study, the stage that establishes whether a drug works and at what dose. Phase 3 trials, which are larger, longer and test hard outcomes, come next, and the authors present these results as supporting phase 3 investigation. Approval decisions typically follow years later, and many phase 2 successes do not survive that process.
Does industry funding matter here?
It is worth knowing. The trial was funded by AstraZeneca, which develops the drug, and company employees appear among the authors. That is standard for drug development and not itself a flaw, since these trials cannot realistically be funded otherwise. It is a reason to weight independent replication heavily and to treat a phase 2 result as promising rather than settled.
References
- Davies MJ, Aroda VR, Rosenstock J, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet (2026).
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity.